HK1143982A1 - 用於製備鈉-葡萄糖協同轉運蛋白 抑制劑的方法和化合物 - Google Patents

用於製備鈉-葡萄糖協同轉運蛋白 抑制劑的方法和化合物

Info

Publication number
HK1143982A1
HK1143982A1 HK10110567.0A HK10110567A HK1143982A1 HK 1143982 A1 HK1143982 A1 HK 1143982A1 HK 10110567 A HK10110567 A HK 10110567A HK 1143982 A1 HK1143982 A1 HK 1143982A1
Authority
HK
Hong Kong
Prior art keywords
transporter
inhibitors
preparation
methods
compounds useful
Prior art date
Application number
HK10110567.0A
Other languages
English (en)
Inventor
Nicole Cathleen Goodwin
Bryce Alden Harrison
Shinya Iimura
Ross Mabon
Qiuling Song
Wenxue Wu
Jie Yan
Haiming Zhang
Matthew Mangzhu Zhao
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of HK1143982A1 publication Critical patent/HK1143982A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
HK10110567.0A 2007-07-26 2010-11-12 用於製備鈉-葡萄糖協同轉運蛋白 抑制劑的方法和化合物 HK1143982A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95212207P 2007-07-26 2007-07-26
PCT/US2008/070250 WO2009014970A1 (en) 2007-07-26 2008-07-17 Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors

Publications (1)

Publication Number Publication Date
HK1143982A1 true HK1143982A1 (zh) 2011-01-21

Family

ID=39877996

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10110567.0A HK1143982A1 (zh) 2007-07-26 2010-11-12 用於製備鈉-葡萄糖協同轉運蛋白 抑制劑的方法和化合物

Country Status (25)

Country Link
US (2) US8026347B2 (zh)
EP (1) EP2183263B1 (zh)
JP (2) JP5653213B2 (zh)
KR (1) KR101663324B1 (zh)
CN (1) CN101801989B (zh)
AR (2) AR067701A1 (zh)
AT (1) ATE530558T1 (zh)
AU (1) AU2008279424B2 (zh)
BR (1) BRPI0813840A2 (zh)
CA (1) CA2694029C (zh)
CL (1) CL2008002169A1 (zh)
CO (1) CO6260141A2 (zh)
DK (1) DK2183263T3 (zh)
EA (1) EA017411B1 (zh)
EC (1) ECSP109987A (zh)
ES (1) ES2375800T3 (zh)
HK (1) HK1143982A1 (zh)
IL (1) IL203209A (zh)
NZ (1) NZ582536A (zh)
PL (1) PL2183263T3 (zh)
PT (1) PT2183263E (zh)
TW (2) TWI506024B (zh)
UA (1) UA107175C2 (zh)
WO (1) WO2009014970A1 (zh)
ZA (1) ZA201000219B (zh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
TWI523652B (zh) 2008-07-15 2016-03-01 泰瑞克公司 氘化苄基苯衍生物及使用方法
TWI472521B (zh) * 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
BRPI0918841B8 (pt) 2008-08-28 2021-05-25 Pfizer derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
SI2496583T1 (sl) 2009-11-02 2015-02-27 Pfizer Inc. Derivati dioksa-biciklo(3.2.1)oktan-2,3,4-triola
PL2498758T3 (pl) 2009-11-13 2019-02-28 Astrazeneca Ab Formulacje tabletek dwuwarstwowych
MX2012005365A (es) 2009-11-13 2012-05-29 Bristol Myers Squibb Co Formulaciones de tableta de liberacion inmediata.
CA2780938A1 (en) 2009-11-13 2011-05-19 Bristol-Myers Squibb Company Reduced mass metformin formulations
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2611442B1 (en) 2010-09-03 2018-07-04 Bristol-Myers Squibb Company Drug formulations using water soluble antioxidants
WO2012106303A1 (en) 2011-02-01 2012-08-09 Bristol-Myers Squibb Company Pharmaceutical formulations including an amine compound
CN103596564B (zh) 2011-06-01 2016-05-04 株式会社绿十字 作为sglt2抑制剂的二苯基甲烷衍生物
WO2012163990A1 (en) 2011-06-03 2012-12-06 Boehringer Ingelheim International Gmbh Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
DK2925735T3 (da) * 2012-11-20 2019-06-17 Lexicon Pharmaceuticals Inc Inhibitorer for natriumglucose-cotransporter 1
PT2981269T (pt) 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
ES2605886T3 (es) 2013-09-27 2017-03-16 Sunshine Lake Pharma Co., Ltd. Derivados de glucopiranosilo y sus usos en medicina
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
CN111494357A (zh) 2013-12-17 2020-08-07 勃林格殷格翰动物保健有限公司 猫科动物中代谢紊乱的治疗
MX2016009421A (es) 2014-01-23 2016-09-16 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabolicos en animales caninos.
HUE050095T2 (hu) 2014-04-01 2020-11-30 Boehringer Ingelheim Vetmedica Gmbh Anyagcsere-rendellenességek kezelése lófélékben
JP6727419B2 (ja) * 2016-05-25 2020-07-22 クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド ナトリウム−グルコース共輸送体阻害薬の新規な結晶形及びその製造方法並びに用途
JP6785523B2 (ja) * 2016-05-28 2020-11-18 ジ・リン・フイ・シェン・バイオ−ファーマシューティカル・カンパニー・リミテッドＪｉ Ｌｉｎ Ｈｕｉ Ｓｈｅｎｇ Ｂｉｏ−Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ナトリウム−グルコース共輸送体２阻害剤の結晶形
HRP20211670T8 (hr) 2016-06-17 2022-03-18 Daewoong Pharmaceutical Co., Ltd. Derivat difenilmetana u kristalnom obliku
WO2018073154A1 (en) 2016-10-19 2018-04-26 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
CN107540685B (zh) * 2017-09-04 2020-05-05 杭州科巢生物科技有限公司 一种Sotagliflozin的制备方法及其中间体
EP3781166A1 (en) 2018-04-17 2021-02-24 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
CN108675976B (zh) * 2018-05-14 2020-07-14 浙江宏元药业股份有限公司 一种6-卤代葡萄糖碳苷及其制备方法和应用
BR112021002523A2 (pt) 2018-08-13 2021-05-04 Daewoong Pharmaceutical Co., Ltd. método para preparar um composto
CN110818722B (zh) * 2018-08-14 2022-12-02 苏州鹏旭医药科技有限公司 三种化合物及其制备方法和在合成索格列净中的用途
JP7441946B2 (ja) 2019-11-28 2024-03-01 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 非ヒト動物の乾乳におけるｓｇｌｔ－２阻害剤の使用
CA3167531A1 (en) 2020-02-17 2021-08-26 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
WO2023006747A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
KR20240041966A (ko) 2021-07-28 2024-04-01 베링거잉겔하임베트메디카게엠베하 고양이를 제외한 비인간 포유류, 특히 개에서 심장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
CN113880701A (zh) * 2021-10-10 2022-01-04 浙江司太立制药股份有限公司 一种抗糖尿病药物中间体及其制备方法
US20230381101A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
BR0109323A (pt) * 2000-03-17 2002-12-24 Kissei Pharmaceutical Derivados de gluco piranosiloxi benzil benzeno, composições medicinais contendo os mesmos e intermediários para a preparação dos derivados
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
AU2002223127A1 (en) * 2000-11-30 2002-06-11 Kissei Pharmaceutical Co., Ltd. Intellectual Property Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CA2444481A1 (en) * 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
US6562791B1 (en) * 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
CN1329407C (zh) * 2002-04-12 2007-08-01 阿奇林医药品公司 合成β－L－5－氟－2′,3′－双脱氧－2′,3′－双脱氢胞嘧啶核苷的方法
BR0310006A (pt) * 2002-08-09 2005-02-15 Taisho Pharmaceutical Co Ltd Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos
BR0317929A (pt) 2003-01-03 2006-04-11 Bristol Myers Squibb Co métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila
US7368475B2 (en) * 2003-03-12 2008-05-06 Kemin Pharma Bvba Furanose-type bicyclic carbohydrates with biological activity
US7202350B2 (en) * 2003-03-14 2007-04-10 Astellas Pharma Inc. C-glycoside derivatives and salts thereof
WO2006018150A1 (de) * 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
ATE445608T1 (de) * 2005-02-23 2009-10-15 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008044268A1 (fr) * 2006-10-05 2008-04-17 Panasonic Corporation Appareil et procédé de transmission
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
TWI472521B (zh) * 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法

Also Published As

Publication number Publication date
AR112669A2 (es) 2019-11-27
AU2008279424B2 (en) 2013-06-13
AR067701A1 (es) 2009-10-21
PT2183263E (pt) 2012-01-11
CN101801989A (zh) 2010-08-11
CA2694029C (en) 2016-10-04
US20120095197A1 (en) 2012-04-19
ES2375800T3 (es) 2012-03-06
TWI419886B (zh) 2013-12-21
ECSP109987A (es) 2010-03-31
IL203209A (en) 2014-02-27
UA107175C2 (uk) 2014-12-10
AU2008279424A1 (en) 2009-01-29
JP2014001230A (ja) 2014-01-09
TW201350473A (zh) 2013-12-16
KR20100040869A (ko) 2010-04-21
CL2008002169A1 (es) 2009-03-20
US8026347B2 (en) 2011-09-27
EP2183263A1 (en) 2010-05-12
PL2183263T3 (pl) 2012-03-30
TW200914434A (en) 2009-04-01
ZA201000219B (en) 2011-03-30
DK2183263T3 (da) 2012-01-30
EA201070186A1 (ru) 2010-08-30
JP5764174B2 (ja) 2015-08-12
ATE530558T1 (de) 2011-11-15
JP5653213B2 (ja) 2015-01-14
CN101801989B (zh) 2015-11-25
CA2694029A1 (en) 2009-01-29
TWI506024B (zh) 2015-11-01
KR101663324B1 (ko) 2016-10-06
US20090030198A1 (en) 2009-01-29
JP2010534661A (ja) 2010-11-11
EA017411B1 (ru) 2012-12-28
BRPI0813840A2 (pt) 2017-06-06
WO2009014970A1 (en) 2009-01-29
NZ582536A (en) 2012-01-12
CO6260141A2 (es) 2011-03-22
US8293878B2 (en) 2012-10-23
EP2183263B1 (en) 2011-10-26

Similar Documents

Publication Publication Date Title
HK1143982A1 (zh) 用於製備鈉-葡萄糖協同轉運蛋白 抑制劑的方法和化合物
HUS1900038I1 (hu) Nátrium-glükóz kotranszporter-2 inhibitorai és alkalmazási eljárásaik
IL190135A0 (en) Process for the preparation of pyrimidinedione derivatives
SI1874746T1 (sl) Derivati 1-N-azacikloalkil-3-fenoksipropana za uporabo pri pripravi psihotropičnih zdravil
ZA200804830B (en) Oil-in-water formulation of avermectins
HK1183020A1 (zh) 鈉-葡萄糖協同轉運蛋白 的抑制劑及其用法
PT1988059E (pt) Processo contínuo para a preparação de nanotubos de titanato de sódio
EP1893625A4 (en) PROCESS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES
IL185939A0 (en) Preparation of paricalcitol
ZA200804264B (en) Process for the preparation of ferri-succinylcasein
ZA200710914B (en) Process for the preparation of sulfonamide derivatives
EP1984327A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF CILASTATIN AND ITS SODIUM SALT
ZA200601910B (en) Process for the preparation of organosilances
GB0605376D0 (en) Preparation for the relief of disease
GB0910201D0 (en) The preparation method of 2-deoxy-l-ribose
IL213474A0 (en) Processes for the preparation of cyclopropyl-amide derivatives
IL198848A0 (en) Sodium salt of disaccharide compound, method for producing the same, and use of the same
EP1866071A4 (en) PERMETHYLATION OF OLIGOSACCHARIDES
ITMI20052464A1 (it) Procedimento per la preparazi9one di norelgestromin norelgestromina
HUP0500570A3 (en) Process for the preparation of (s)-(-)-amlodipine
ZA200706203B (en) Processes and compounds for the preparation of substituted naphthylindole derivatives
AU2007322712B2 (en) Sodium salt of disaccharide compound, method for producing the same, and use of the same
GB0517353D0 (en) Modification of capsular saccharides
GB0508655D0 (en) Improvements relating to the administration of materials through the skin
IL187584A0 (en) Pediatric formulation of topiramate